Clinical Trials Browser

Terminated × Breast Carcinoma In Situ × 1 year × Clear all

NCT05755269 2026-05-01

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Phase 2 Terminated

Breast Carcinoma In Situ, Breast Neoplasms

NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Phase 2 Terminated

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms